$MTNB News

Matinas Biopharma Files Prospectus For Offering $150M Mixed Shelf

Matinas BioPharma Hldgs Q1 EPS $(0.30) Up From $(0.33) YoY

Matinas BioPharma Hldgs Q4 EPS $(0.26) Up From $(1.68) YoY

Matinas BioPharma CFO Keith Kucinski Resigns; CEO Jerome Jabbour Appointed Interim CFO

Matinas Biopharma CFO Keith Kucinski To Resign Effective January 17, 2026

Matinas BioPharma Hldgs Q3 EPS $(0.40) Up From $(0.85) YoY

Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203

Matinas BioPharma Doubles Authorized Common Shares To 500M Following Shareholder Approval

Matinas Biopharma Holdings shares are trading higher after the company announced it entered into a deal for the acquisition of certain preferred stock.

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Matinas BioPharma Enters Deal For Acquisition Of Certain Preferred Stock, Appoints Robin L. Smith To Board

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

111 Equity Group Increases Stake To 5.17% In Matinas Biopharma As Strategic Review Underway Including Asset Sale Of MAT2203; $10.3M Cash Reported Which Would Equate To Roughly $2.13 Cash Per Share Value

Matinas BioPharma Receives NYSE Noncompliance Notice

Matinas Biopharma Shares Resume Trade

Matinas BioPharma Shares Halted To The Downside; Stock Now Up 3.15%

Matinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners

Matinas BioPharma just downgraded at Alliance Global Partners, here's why

Maxim Group Downgrades Matinas BioPharma Hldgs to Hold

Matinas BioPharma plunges as deal for lead asset falls apart